Abel puts a big chunk of Berkshire's cash to work

Berkshire reduced cash by 8.0% to $365.5B in Q2 (and 3.8% to $359.2B on a T-bill-adjusted basis) even as it stepped up capital allocation, including $4.5B of share buybacks—below some estimates but far above the prior quarter. Operating earnings rose 16% to $12.98B, led by Berkshire Hathaway Energy (+27%) and BNSF (+6%), partially offset by weaker insurance results (underwriting -13%, insurance investment income -9%, GEICO underwriting -45%). The article also notes broader net equity buying of about $20B, including a $10B Alphabet (Google) investment, plus an estimated additional $3.4B buybacks in July.

Analysis

The important signal is not that Berkshire spent cash, but that it spent in a way that shortens the market’s runway for the “dead money” critique. Sustained repurchases plus a net return to equity buying can compress the conglomerate discount because they imply the float is no longer waiting passively on a single heroic acquisition; per-share compounding now has a visible capital-return lever. That supports BRK.B over the next 1-3 months, especially if the coming 13F shows the new buying is concentrated in high-quality, cash-generative franchises rather than a one-off portfolio tweak.

The counterpoint is that one quarter does not change the structural math: Berkshire still has enormous optionality, and the market may overread a modest step-up in buybacks as a regime change. The real 6-18 month bull case is not the cash balance itself, but whether Abel proves he can redeploy excess capital faster than the intrinsic-value growth rate of the operating businesses. If insurance underwriting stays weak or buybacks fade back toward token levels, the stock likely reverts to trading as a slow-moving financial with a quality premium rather than a true catalyst story.

DVA looks like a second-order loser where the initial drawdown may only partially reflect the risk. The immediate mechanical sale is noise; the real issue is that the revenue-per-treatment pressure from patient mix deterioration is a lagging indicator of reimbursement fragility, which can bleed into the next 1-2 quarters via lower utilization and less favorable payer mix. GOOGL gets a sentiment tailwind from a large value investor validation, but the market should not extrapolate a valuation rerating from a position that is too small to change fundamentals; that said, it may help dampen the perceived regulatory overhang at the margin if other long-only institutions follow the signal.

Key Decisions for Investors

• Long BRK.B vs. SPY on any post-earnings fade over the next 5-10 trading days; thesis is narrowing of the conglomerate discount as buybacks become a recurring capital-return tool. Risk/reward improves if the stock retraces the initial rally, and falsifier is a return to near-zero repurchases next quarter.
• Add to BRK.B only if the forthcoming 13F confirms net equity accumulation into high-quality compounders; otherwise treat this as a signal, not a structural break. Use a 1-3 month horizon and keep size modest until capital-deployment cadence is proven.
• Buy DVA put spreads or short DVA on rebounds over the next 2-6 weeks; the stock likely still has downside as reimbursement and mix pressure works through next quarter. Falsifier: stabilization in revenue per treatment or management guidance that offsets the mix hit faster than expected.
• Do not chase GOOGL on this headline alone; if anything, use it as a watch item for incremental institutional sponsorship rather than a standalone catalyst. Best expression is a patient long only on market weakness, not immediate momentum entry.
• Set an alert on Berkshire buyback cadence and cash balance next quarter: if repurchases stay above the prior run-rate while cash continues to fall, BRK.B can re-rate over 6-18 months; if not, fade the move.